Estrogens and Progestins: Receptors, Clinical Indications and Menopausal Hormone Therapy

Medical education review • Updated 10 November 2026. Not a substitute for individualized clinical assessment and local prescribing guidance.

Overview

Estrogens and progestogens are sex-steroid hormones or analogues with effects on reproductive tissues, bone and central neuroendocrine pathways. Clinical use includes menopausal symptoms, contraception, cycle regulation, endometrial protection and selected endocrine indications. Their risks depend on molecule, dose, route, duration, uterus status and patient factors [1–3].

Chemical and pharmacologic classification

  • Estrogens: estradiol (E2), estrone (E1), estriol (E3); pharmaceutical estrogens include 17β-estradiol, conjugated equine estrogens and ethinyl estradiol. Conjugated estrogens are a mixture of estrogen sulfates, not synonymous with all synthetic estrogens.
  • Progestogens: natural micronized progesterone and synthetic progestins including medroxyprogesterone acetate, norethindrone, levonorgestrel, desogestrel and drospirenone. Chemical families vary: levonorgestrel is a 19-nortestosterone derivative, while drospirenone is spironolactone-related; older generation-based categories do not replace individual safety data [1].

Receptors and molecular effects

Estrogens bind intracellular ERα and ERβ, affecting gene transcription and also mediating rapid membrane-associated signaling; tissue effects depend on receptor distribution and coregulators. Progesterone binds PR-A and PR-B and modulates endometrial secretory transformation, cervical mucus, uterine contractility and hypothalamic-pituitary feedback. Unopposed systemic estrogen can stimulate endometrial proliferation in patients with an intact uterus, requiring adequate progestogen protection when systemic estrogen is prescribed for menopause [1,2].

Menopausal hormone therapy

Systemic estrogen therapy is the most effective treatment for troublesome vasomotor menopausal symptoms and can prevent bone loss in selected patients. For patients with a uterus, add an appropriate progestogen to reduce endometrial hyperplasia/cancer risk; hysterectomized patients generally do not require it solely for endometrial protection. Local low-dose vaginal estrogen may treat genitourinary syndrome with low systemic exposure and generally does not require routine progestogen. Therapy should be individualized using age, time since menopause, vascular/cancer risk, route and personal preferences rather than offered as universal cardiovascular prevention [2,3].

Contraception is distinct from menopausal therapy

Contraceptive-dose combined hormonal formulations and menopausal hormone therapy differ in approved purpose, dose, hormone composition and risk assessment. Hormone therapy does not reliably provide contraception. Some progestogens are also prescribed for abnormal uterine bleeding and endometriosis under indication-specific protocols [1,2].

Adverse effects and safety

Oral systemic estrogen can increase venous thrombosis risk; transdermal estradiol may have lower thrombogenic effect in suitable patients but evidence is not identical across outcomes. Breast cancer, stroke, coronary disease, active liver disease and previous thrombosis considerations require personalized risk review. Progestogens can cause breakthrough bleeding, mood symptoms and breast tenderness. Unexplained postmenopausal bleeding always needs evaluation. Avoid pregnancy exposure to nonindicated menopausal formulations [2,3].

Drug interactions and pharmacokinetics

Oral estrogens undergo hepatic first pass and modify hepatic protein synthesis; transdermal preparations avoid much of this first-pass effect. Estrogen/progestin metabolism may be affected by enzyme inducers such as rifampicin and some antiseizure medicines; assess the specific hormone product and clinical indication [1].

References

  1. Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
  2. The North American Menopause Society Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767–794. doi:10.1097/GME.0000000000002028. Available from: https://doi.org/10.1097/GME.0000000000002028
  3. National Institute for Health and Care Excellence. Menopause: identification and management. NICE guideline NG23. Available from: https://www.nice.org.uk/guidance/ng23/chapter/recommendations
Medical & AI Disclaimer

The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.

We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.

Leave a Reply

Your email address will not be published. Required fields are marked *